Read the latest NeuroTrax news

Stay current with scientific publications, case studies, and findings featuring the NeuroTrax cognitive assessment platform.

NeuroTrax continues to advance brain health assessment with precise measurement across multiple domains.

Oct 29, 2026

Mind the Awareness Gap: Digital Neurometrics Promote Self-Awareness of Cognitive Decline

NeuroTrax Science Team and Glen M. Doniger, PhD

Video Summary: https://youtu.be/Xt8amo6sZBI

Among the most consequential barriers to early detection of cognitive decline is the patient’s inability to recognize that a problem exists. Impaired self-awareness, often referred to as anosognosia, is the diminished ability to recognize one’s own cognitive, memory, or functional deficits. In a recent randomized controlled trial of older adults with mild cognitive impairment (MCI), 54 participants demonstrated impaired awareness at baseline. Patients who overestimate their abilities may delay seeking care or resist strategies intended to protect their safety and independence (1). Impaired self-awareness is also observed across neurodegenerative conditions, including Parkinson’s disease, reinforcing its broader clinical relevance (2).

This creates a fundamental challenge for clinicians. When subjective self-report is compromised, informal questioning alone may not provide an accurate picture of cognitive health. The problem is particularly important in primary care, where the Medicare Annual Wellness Visit creates an opportunity for early detection. Although approximately 80% of surveyed beneficiaries reported completing an Annual Wellness Visit, only 31% reported receiving a structured cognitive assessment (3). Patients at elevated risk were no more likely to receive one.

Objective digital neurometrics can help close this gap. NeuroTrax quantifies performance across multiple cognitive domains and compares results with age- and education-adjusted normative data. A validated 30-minute battery has demonstrated the ability to distinguish cognitively healthy adults, individuals with MCI, and those with mild dementia, providing clinicians with an efficient and interpretable cognitive profile (4). Rather than depending exclusively on what a patient notices or reports, clinicians gain an objective benchmark for discussing cognitive strengths, weaknesses, and changes over time.

The clinical value of that benchmark is highlighted by Dwolatzky and colleagues’ 2026 randomized controlled trial. The study assigned 114 older adults with MCI to the Feuerstein Instrumental Enrichment (FIE) metacognitive training program or one of two active control groups. Self-awareness was measured as the absolute discrepancy between objective NeuroTrax memory performance and subjective symptom appraisal on the CogSym questionnaire. A larger discrepancy indicated that the participant’s perception was less consistent with objective performance.

Among participants with impaired awareness at baseline, 15 weeks of FIE training reduced the discrepancy score from 1.58 to 0.87, a statistically significant improvement with a large effect size. The improvement was maintained at the two-month follow-up, while gains in the active control groups were minimal and not sustained (1). The clinical implication is important: self-awareness in MCI may be modifiable, but recalibration requires an objective, standardized benchmark against which personal perceptions can be evaluated.

NeuroTrax provides that benchmark through standardized multidomain testing, automated scoring, and immediately available clinical reports. Its established validity supports the detection of MCI, while alternate forms support repeated assessment with reduced practice effects (5,6). Periodic testing can therefore help clinicians distinguish subjective concern from measurable impairment and identify change before it becomes obvious through a major functional failure.

Making cognitive change visible can support earlier evaluation of reversible contributors, timely referral for specialist assessment, initiation of cognitive or lifestyle interventions, and informed conversations about medication management, financial decisions, driving, and fall prevention. Digital neurometrics do more than identify cognitive decline. They provide an objective anchor that can help patients, families, and clinicians recognize it, respond to it, and preserve autonomy for as long as possible.

References:

[1] Dwolatzky, T., Devisheim, H., Feuerstein, R.S., and Cohen, S. (2026). Enhancing self-awareness in older adults with mild cognitive impairment: A preliminary randomized controlled trial of the Feuerstein Instrumental Enrichment program. International Journal of Geriatric Psychiatry, 41(9), e70256. DOI: 10.1002/gps.70256

[2] Maier, F., Greuel, A., Hoock, M., Kaur, R., Tahmasian, M., Schwartz, F., Csoti, I., Jessen, F., Drzezga, A., van Eimeren, T., Timmermann, L., and Eggers, C. (2023). Impaired self-awareness of cognitive deficits in Parkinson’s disease relates to cingulate cortex dysfunction. Psychological Medicine, 53(4), 1244–1253. DOI: 10.1017/S0033291721002875

[3] Liu, Y., Ozawa, T., and Mattke, S. (2025). Usage patterns of cognitive assessments during Medicare’s Annual Wellness Visit: A national survey. Alzheimer’s & Dementia, 21(2), e14539. DOI: 10.1002/alz.14539

[4] Doniger, G.M., Zucker, D.M., Schweiger, A., Dwolatzky, T., Chertkow, H., Crystal, H., and Simon, E.S. (2005). Towards practical cognitive assessment for detection of early dementia: A 30-minute computerized battery discriminates as well as longer testing. Current Alzheimer Research, 2(2), 117–124. DOI: 10.2174/1567205053585792

[5] Dwolatzky, T., Whitehead, V., Doniger, G.M., Simon, E.S., Schweiger, A., Jaffe, D., and Chertkow, H. (2003). Validity of a novel computerized cognitive battery for mild cognitive impairment. BMC Geriatrics, 3, 4. DOI: 10.1186/1471-2318-3-4

[6] Schweiger, A., Doniger, G.M., Dwolatzky, T., Jaffe, D., and Simon, E.S. (2003). Reliability of a novel computerized neuropsychological battery for mild cognitive impairment. Acta Neuropsychologica, 1(4), 407–413.

Continue reading

Oct 14, 2026

NeuroTrax as Objective Cognitive Evidence in Legal Proceedings

NeuroTrax Science Team and Glen M. Doniger, PhD

Video Summary: https://youtu.be/yautJzkWcd8

When cognitive impairment becomes relevant to a legal claim, subjective symptoms alone may not provide the objective evidence needed to establish the nature, extent, or functional impact of an injury. Standardized cognitive testing can help experts translate reported difficulties into measurable performance across such domains as memory, executive function, attention, processing speed, visual spatial ability, verbal function, and motor skills.

NeuroTrax has an established record of being considered as cognitive evidence in legal proceedings. It has been incorporated into federal evidentiary records, presented as part of expert testimony in jury trials, subjected to cross-examination, and reviewed by courts evaluating alleged cognitive impairment.

Under Federal Rule of Evidence 702, expert testimony must help the factfinder, be based on sufficient facts or data, and reflect the reliable application of reliable principles and methods. Under Daubert v. Merrell Dow Pharmaceuticals, courts may consider whether a methodology has been tested, subjected to peer review and publication, governed by appropriate standards, associated with a known or potential error rate, and accepted within the relevant scientific community. These factors are flexible, and admissibility ultimately depends on how the expert applies the methodology to the facts of the individual case (1,2). Thus the admissibility of NeuroTrax or any assessment platform depends on the expert’s qualifications, the scientific foundation of the methodology, the quality of the data, and the appropriateness of the interpretation.

Perhaps the strongest example of NeuroTrax’s admissibility is Barnett v. National Continental Insurance Co. Defendants filed a Daubert motion challenging a neurologist’s methodology and specifically criticized his reliance on a NeuroTrax cognitive study. They argued that NeuroTrax and other testing could not determine when the alleged traumatic brain injury occurred and therefore could not independently establish causation. The court rejected the assumption that NeuroTrax was the sole basis for the expert’s opinion. It found that the neurologist had also considered the patient’s history, clinical findings, other testing, medical literature, and alternative causes. The court concluded that the expert’s methodology was “sound and appropriate” and denied the motion to exclude his testimony. The ruling allowed NeuroTrax-supported expert evidence following a direct reliability challenge (3).

In Kang v. Romeo, a federal court considered NeuroTrax results more substantively. The assessment identified impaired memory and low-average executive, verbal, and global cognitive functioning. Together with other neuropsychological findings and MRI evidence of brain atrophy, the results contributed to the court’s conclusion that the plaintiff had produced sufficient evidence to raise a genuine dispute regarding a significant limitation from an alleged brain injury. Summary judgment on the relevant head-injury claim was therefore denied (4).

NeuroTrax has also been presented directly to juries. In Barra v. MTA, a neuropsychologist explained the computerized battery, the cognitive domains assessed, the patient’s results, and the methods used to evaluate effort. The assessment formed part of live expert testimony and was subjected to cross-examination. Thus in addition to its acceptance in medical records, NeuroTrax evidence has been scrutinized via the adversarial trial process (5).

The forensic value of cognitive data depends on whether the results reflect valid effort. Peer-reviewed research in traumatic brain injury patients in litigation developed and validated a performance-validity algorithm embedded within the NeuroTrax assessment, addressing negative response bias and credibility of test performance, central concerns in forensic neuropsychological assessment (6).

These legal and scientific reports support a clear conclusion: NeuroTrax is a viable source of objective cognitive evidence when it is administered appropriately, interpreted by a qualified professional, and integrated with clinical history, behavioral observations, medical evidence, and other relevant testing. Notably, its value in legal proceedings lies not in independently diagnosing an injury or establishing causation, but in providing valid, standardized, multidomain measurements that can strengthen a well-supported expert opinion.

References:

[1] Federal Rule of Evidence 702. (2023). Testimony by expert witnesses. Federal Rules of Evidence.

[2] Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993).

[3] Barnett v. National Continental Insurance Co., No. 3:17-CV-153-JWD-EWD, Document 53 (U.S. District Court for the Middle District of Louisiana, January 8, 2019).

[4] Kang v. Romeo, No. 18-CV-4033 (ARR) (SMG), Document 40 (U.S. District Court for the Eastern District of New York, August 14, 2020).

[5] Barra v. Metropolitan Transportation Authority, Index No. 102339/11, Trial Transcript (New York Supreme Court, New York County, April 8, 2016).

[6] Bar-Hen, M., Doniger, G.M., Golzad, M., Geva, N., and Schweiger, A. (2015). Empirically derived algorithm for performance validity assessment embedded in a widely used neuropsychological battery: Validation among TBI patients in litigation. Journal of Clinical and Experimental Neuropsychology, 37(10), 1086–1097. DOI: 10.1080/13803395.2015.1078294

Continue reading